Emesis Clinical Trial
Official title:
A Prospective, Randomized Trial to Evaluate the Efficacy of High Protein Intake on the Incidence of Emesis and Promotion of Patient Satisfaction After Epidural Analgesia for Labor
The purpose of our study is to determine if the incidence of emesis can be lowered with the addition of a high protein drink during labor. Emesis and nausea are the leading causes of parturient dissatisfaction, results in a delay of returning to normal, daily living and can hugely impact the mother's postpartum experience. To date, no studies have been done on the relationship of protein intake during labor and incidence of emesis. To the best of our knowledge, the use of a high protein drink during labor has not been evaluated in the literature.
The investigators plan to enroll women (n=150) who requested epidural anesthesia for labor. After placement of their labor epidural catheter, parturients will be randomized by a computer generated number table into one of two groups. Group P - high protein drink with 30 grams of protein and ice chips PRN, or Group C - control group consisting of ice chips PRN. The protein drink that will be used is Premier Nutrition Protein Shake, which contains 30 grams of protein in 11 ounces. Measured variables will include; nausea and emesis at epidural placement, at hourly intervals until delivery, and 1 hour post delivery. Nausea will be evaluated using a visual analog scale (VAS); 0 = no nausea and 10 = worst nausea ever. Episodes of emesis will be recorded as (yes/no). The parturient will be seen the day following delivery and evaluated for overall patient satisfaction. Parturients will rate their satisfaction level using a scale from 0-100 with 0=not satisfied and 100=very satisfied. The investigators believe that the incidence of emesis will be decreased in parturients who receive high protein intake during labor, and overall patient satisfaction will be increased. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01913990 -
Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients.
|
Phase 4 | |
Terminated |
NCT00869310 -
Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis
|
Phase 3 | |
Terminated |
NCT00869973 -
Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients
|
Phase 3 | |
Completed |
NCT04719286 -
MinSafeStart - Decision Aid Tool for Better Treatment of Nausea and Vomiting During Pregnancy
|
N/A | |
Completed |
NCT01046240 -
Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Palonosetron in Cancer Treated With Chemotherapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT03478605 -
Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis
|
Phase 2 | |
Recruiting |
NCT04564144 -
Evaluation of Meclizine Orodispersible Tablet Pharmacokinetic in Human Volunteers
|
Phase 1/Phase 2 | |
Terminated |
NCT01148264 -
Comparison of Olanzapine and Metoclopramide For Treatment Of bReakThrough Emesis
|
Phase 2 | |
Completed |
NCT01509417 -
Different Feeding Methods After Pyloromyotomy
|
N/A | |
Completed |
NCT00152867 -
Dexamethasone Study: Impact on Quality of Life of Continuing Dexamethasone Following Emetogenic Chemotherapy
|
Phase 3 | |
Completed |
NCT04182750 -
Promoting Safe Medication Use in Pregnancy in the Era of Real-World Data - The SafeStart Study
|
N/A | |
Completed |
NCT02980289 -
DAnish Nausea Study In Advanced Cancer-Epidemiology: A Danish Multicenter Trial to Investigate the Prevalence and Treatment of Nausea and/or Vomiting in Patients With Advanced Cancer.
|
||
Completed |
NCT02602080 -
Post- Surgery Recovery: Nerve Blocks w/ Sedation vs. Nerve Block w/ Either Sedation/Gen. Anesthesia
|
||
Completed |
NCT04585841 -
The Effect of Cannabidiol on Lean Body Mass in Patients Receiving Chemotherapy
|
Phase 1 | |
Not yet recruiting |
NCT02407600 -
Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy
|
Phase 2 |